Publications

5491 Results

National impact of the COVID-19 pandemic on clinical trial staff attrition: Results of the SWOG Cancer Research Network survey of Oncology Research Professionals

Authors
D Dizon;C Szczepanek;D Petrylak;D Sparks;C Tangen;P Lara;IM Thompson;CD Blanke
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 11049), poster 240; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022

Assessing Intermediate Clinical Endpoints (ICE) as Potential Surrogates for Overall Survival (OS) in men with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Authors
S Halabi;A Roy;L Rydzewska;P Godolphin;M Parmar;M Hussain;C Tangen;I Thompson;W Xie;M Carducci;M Smith;M Morris;G Gravis;D Dearnaley;P Verhagen;T Goto;N James;M Buyse;J Tierney;C Sweeney
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 5006), abst 5006; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-9346

Vitamin D Insufficiency as a Peripheral Neuropathy Risk Factor in White and Black Patients in SWOG 0221

Authors
C-S Chen;G Zirpoli;S McCann;W Barlow;GT Budd;L Pusztai;G Hortobagyi;A Godwin;A Thompson;C Ambrosone;K Stringer;D Hertz
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 12023), poster 269; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Breast
Study Number(s)
S0221

Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements

Authors
K Blenman;K Fanucci;Y Bai;V Pelekanou;Z Nahleh;S Shafi;S Burela;W Barlow;P Sharma;A Thompson;A Godwin;D Rimm;G Hortobagyi;L Pusztai
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 594), poster 365; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Breast
Study Number(s)
S0800

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (SWOG S0931, NCT01120249)

Authors
CW Ryan;C Tangen;E Heath;M Stein;M Meng;A Alva;S Pal;I Puzanov;J Clark;T Choueiri;N Agarwal;R Uzzo;N Haas;T Synold;M Plets;U Vaishampayan;B Shuch;N Vogelzang;I Thompson;P Lara
Journal / Conference
J Clin Oncol 40, 2022 (suppl 17; abstr LBA4500), abst. LBA4500; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S0931

Follow-Up Analysis of the Randomized Phase II Trial of Bortezomib, Lenalidomide, Dexamthasone with/without Elotuzumab for Newly Diagnosed, High Risk Multiple Myeloma (SWOG-1211)

Authors
S Usmani;A Hoering;S Ailawadhi;R Sexton;B Lipe;J Valent;M Rosenzweig;J Zonder;M Dhodapkar;N Callandar;T Zimmerman;P Voorhees;B Durie;V Rajkumar;P Richardson;R Orlowski
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 8054), poster 477; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Myeloma
Study Number(s)
S1211

Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from SWOG S1216, a phase III trial of ADT with or without orteronel

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;N Vogelzang;N Agarwal
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 5071), poster 254; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S1216

S1314 Correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation

Authors
E Plimack;C Tangen;M Plets;R Kokate;J Xiu;C Nabhan;E Ross;E Grundy;W Choi;C Dinney;I-L Lee;MS Lucia;T Flaig;D McConkey
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 4581), poster 72; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S1314

Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for Previously Treated Stage IV or recurrent Squamous Cell Lung Cancer patients from the Phase III SWOG LungMAP S1400I trial

Authors
E Parra;D Duose;J Zhang;M Redman;R Lazcano;M Piubelli;C Laberiana Fernandez;B Zhang;J Lindsay;R Moravec;K Kannan;R Luthra;G Al-Atrash;R Herbst;I Wistuba;S Gettinger;L Bazhenova;J Lee;J Zhang;C Haymaker
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9046), poster 34; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab

Authors
E Gonzalez-Kozlova;H-H Huang;M Redman;R Herbst;S Gettinger;L Bazhenova;H Xie;M Patel;K Nie;J Harris;C Argueta;K Kelly;E Cerami;R Biswas;S Van Nostrand;R Moravic;D Del Valle;S Kim-Schulze;S Gnjatic
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr 9044), poster 32; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I